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ABSTRACT 
Influenza and pneumococcal infections are important causes 
of morbidity and mortality in the older adult population, partic- 
ularly in developed countries. The causative agents pose unique 
challenges for the formulation and manufacture of vaccines. 
Influenza vaccines must be regularly updated because of anti- 
genie changes in the circulating viruses, and pneumococcal 
vaccines that consist of capsular polysaccharides must con- 
tain several antigens if they are to protect against multiple 
serotypes of Streptococcus pneumoniae. Nevertheless, safe 
vaccines which provide a good measure of protection against 
the severe sequelae of infection have been developed for both 
infections, and it has now been shown that these vaccines are 
more cost-effective than most other medical interventions in 
the older adult population. However, in most countries the vac- 
cines remain largely under-utilized. Research toward improved 
vaccines is currently in progress; however, to gain the great- 
est benefits from both current and future vaccines requires a 
better understanding of the factors influencing their use. 
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On the bicentenary of Jenner’s momentous experiment 
in vaccination, it is appropriate to celebrate what has 
been achieved in the intervening 200 years. It has been 
said that vaccination, particularly pediatric vaccination, 
has led to greater improvements in public health this 
century than any other medical intervention, including 
the introduction of antibiotics.’ Whereas there is ongo- 
ing development and introduction of new and improved 
vaccines and indications that we may be on the brink of 
a revolution in vaccination with DNA vaccines, it is dis- 
appointing that even in developed countries there is a 
tendency to neglect adult vaccination. 
Although there have been some improvements in 
vaccination levels in recent years, influenza and pneu- 
mococcal infections still represent major causes of vac- 
cine-preventable morbidity and mortality.z It has been 
suggested that the reasons for inadequate use of the 
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available influenza and pneumococcal vaccines include 
poor awareness of the impact of the diseases, unwar- 
ranted fear of side effects, poor perception of vaccine 
effectiveness, and a tendency to focus on, curative rather 
than preventive medicine. lz3 Where surveys have been 
conducted, it has been found that the attitude of the pri- 
mary health care giver has the greatest influence on 
patient acceptance of vaccination4 
This article reviews the substantial impact of influ- 
enza and pneumonia; the development, safety, and effi- 
cacy of current vaccines; and prospects for future, 
improved vaccines. By highlighting the overwhelming 
evidence of vaccine safety and efficacy and the strong 
economic arguments in favor of vaccination, the article 
aims to provide useful background to those involved in 
the delivery of primary care. 
IMPACT OF INFLUENZA AND PNEUMOCOCCAL 
INFECTIONS 
In the adult population, the greatest effect of influenza 
and pneumococcal infections is seen among older adults 
and those with certain predisposing conditions, includ- 
ing heart, lung, and kidney disease; diabetes; and 
immunosuppressive conditions. Mortality provides the 
most visible measure of the impact of these two diseases, 
and it has been recognized for some time that influenza 
outbreaks are characteristically associated with excess 
mortality, much of which is attributed to underlying 
chronic diseases.j-7 It has been shown that there are 
10,000 to 20,000 influenza-associated deaths annually in 
the United States and up to 40,000 during the more seri- 
ous outbreaks.* The great majority of these deaths 
(SO-90%) occur in people over the age of 64 years.9~10 
Studies in a number of countries indicate that annual 
influenza-associated deaths are on the order of 100 per 
100,000 in the over 64-year-old population, and the fre- 
quency increases with increasing age and the presence 
of underlying risk conditions.5-7 Estimated deaths asso- 
ciated with pneumococcal infection in the United States 
are similar to those for influenza, at 40,000 per year,‘i 
and again, the fatality rate increases with age and under- 
lying risk factors. 
The full economic impact of influenza and pneumo- 
coccal disease is more difficult to assess. Conservative 
estimates put the direct annual costs of hospitalization in 
the United States for influenza at $600 million in 198411 
and for pneumonia at $500 million in 1986.12 The total 
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annual economic cost of influenza alone was conserva- 
tively estimated as US $3 to 5 billion,13 and this may be 
as high as US $12 billion in severe outbreaks.” 
CHARACTERISTICS OF CAUSATIVE ORGANISMS 
AND DEVELOPMENT OF VACCINES 
The development of influenza and pneumococcal vac- 
cines dates back over 50 years, and both vaccines pose 
unique production problems. Most of the common vac- 
cine-preventable diseases are caused by a single serologic 
type of an antigenically stable microorganism; therefore, 
it is relatively straightforward, once a vaccine has been 
developed, to produce consistent vaccine lots as required. 
In the case of influenza, however, the causative viruses 
have an exceptional propensity for antigenic change and, 
in the case of Streptococcuspneumoniae, the bacterium 
occurs in 90 distinct serologic types.‘* 
There are two major types of influenza virus respon- 
sible for infection in man, type A and type B, and both 
display continued mutational changes in their two surface 
antigens. In addition, influenza A exists as a number of 
antigenically distinct subtypes and, at irregular intervals, 
a new subtype becomes established in the human pop- 
ulation. On such occasions, worldwide pandemic spread 
occurs within a few months, usually before adequate sup- 
plies of vaccine can be manufactured. It is now believed 
that the new human subtypes of influenza A are derived 
by genetic reassortment between human influenza 
viruses and the large pool of influenza A virus subtypes 
that exist in aquatic birds. 
It has been known from the earliest days of influenza 
vaccine production that the level of protection produced 
by the vaccine is dependent on the closeness of match 
between the vaccine viruses and circulating strains. Reg- 
ular strain updating is achieved through the worldwide 
surveillance network established by the World Health 
Organization (WHO) in 1947. Influenza vaccines are still 
prepared from virus grown in embryonated eggs; this 
imposes a number of constraints on the process and 
requires a relatively long lead-time for production. There- 
fore, it is necessary to determine the formulation for use 
in the manufacture of vaccines for the Northern Hemi- 
sphere winter as early as the preceding January or Febru- 
ary. Despite the relatively long time between determining 
the formulation and use of the vaccine, good strain 
matches with the epidemic viruses have been achieved in 
recent years.* 
Current influenza vaccines are prepared from egg- 
grown virus that has been concentrated and highly puri- 
fied, usually by an ultracentrifuge process. The virus is 
chemically inactivated and in most cases is dissociated 
chemically (referred to as splitting) to remove a low level 
of systemic toxicity observed with whole virus vaccines. l5 
Some vaccines are further purified to contain only the 
surface antigens of the viru~,~~ although there is no evi- 
dence that this confers any additional advantage. 
The bacterium S. pneumoniae was first isolated in 
1881. Morphologically, pneumococci are typical gram- 
positive streptococci that occur in pairs or short chains. 
The surface of the organism consists of three distinguish- 
able layers, a plasma membrane, a cell wall containing a 
peptidoglycan backbone, and a thick polysaccharide cap- 
sule consisting of high molecular weight polymers of 
repeating oligosaccharides. The polysaccharide capsule 
determines both the virulence of the organism and its 
antigenic specificity, and a total of 90 distinct capsular 
types have been recognized.‘* Fortunately not all sero- 
types are equally invasive in man, and the frequency of 
occurrence in invasive infection in American studies was 
used as the basis for selecting, initially in 1977, a 14- 
valent vaccine which covered over 80% of such infec- 
tions and, in 1984, a 23-valent preparation that covered 
88% of the most frequently reported types in the United 
States.” However, strain frequency varies in different 
countries; for example, it has been reported that the cur- 
rent 23-valent preparation covers only 62.9% of isolates 
in Tai~an.‘~ Therefore, vaccines may not be universally 
acceptable for different geographic regions. 
Although human vaccination against pneumococcal 
infection dates back to 1912 and the studies conducted 
by Wright and others using whole bacterial vaccine in 
South African coal miners,19 it was in 1938 that the first 
reports were published of human trials with a bivalent 
purified polysaccharide vaccine.2o Following the intro- 
duction of sulfonamides and antibiotics, interest in vac- 
cine development slowed, despite a number of successful 
trials of multivalent capsular vaccines. Subsequently, the 
finding that mortality from pneumococcal bacteria 
remained high regardless of antibiotic therapy was the 
stimulus for the further development and registration of 
the 14-valent and then the 23-valent vaccine, which is 
used today, and more recently, widespread reports of 
antibiotic-resistant strains provide an additional incentive 
for vaccination.21~22 The current vaccine is a cocktail con- 
taining 25 ug of each of the specified capsular polysac- 
charides in essentially chemically pure form. Each antigen 
has to meet stringent test requirements for freedom from 
proteins and nucleic acids, molecular size characteriza- 
tion, and chemical characterization. 
INFLUENZA VACCINES 
Both the lay public and medical practitioners tended to 
regard influenza vaccines as unduly reactive and poorly 
efficacious.23,24 Although earlier, less pure vaccines clearly 
did produce systemic reactions, these reactions occur at 
a much reduced level with highly purified whole virus 
vaccines and are essentially absent from split and subunit 
vaccines.25~26 Controlled studies in both young and older 
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adults have confirmed the safety of today’s split product 
and subunit vaccines. Two recent randomized placebo- 
controlled trials were unable to detect any significant dif- 
ference in systemic reactions between vaccine and 
placebo,27,28 and although there was a significantly higher 
level of local reactions observed in vaccine recipients, 
these were all mild and transitory. 
The majority of field trials to determine the protec- 
tive efficacy of influenza vaccines have been carried out 
in young healthy individuals. Such trials usually have pro- 
vided estimates of vaccine effectiveness in preventing 
infection ranging from 60 to 90%, providing there had 
been a good match between the circulating viruses and 
the vaccine strains. On the other hand, protection against 
infection in elderly subjects has been found to be con- 
siderably lower, possibly on the order of only 23 to 
33%.29-31 These figures come largely from observational 
studies, as many countries had adopted recommenda- 
tions for annual vaccination of older adults in the 1960s 
and ethical considerations precluded placebo-controlled 
studies of vaccine efficacy in this target population. As a 
consequence, a number of retrospective or observational 
studies have been carried out in recent years to investi- 
gate the effectiveness of influenza vaccination in elderly 
subjects. These have uniformly shown the vaccines to 
be highly effective in preventing severe outcomes of 
influenza infection. A recent meta-analysis of 20 cohort 
studies on influenza vaccine effectiveness in elderly peo- 
ple published in the last 20 years provided pooled esti- 
mates of 56% reduction in respiratory illness, 53% 
reduction in pneumonia, 50% effectiveness in prevent- 
ing hospitalization, and 68% effectiveness in preventing 
death.32 
Three recent studies provide additional important 
information on the effectiveness of vaccination.33-35 A 3- 
year serial cohort study of over 50,000 elderly people 
showed that vaccination was associated with a 48 to 57% 
reduction in hospitalization for influenza and pneumonia 
and a 39 to 54% reduction in mortality from all causes, 
and surprisingly, these benefits were also seen in a 
nonepidemic year.33 The same study also showed that 
vaccination reduced hospitalization due to cardiac fail- 
ure in a year when influenza A was epidemic. A recent 
British study that reviewed the records of 315 patients 
who died from influenza in 1989-90, along with 777 
matched controls who died a year later, found that vac- 
cination reduced mortality by 41%; however, the reduc- 
tion in mortality was 75% in those who had received 
vaccine previously. 34 In addition, the only randomized 
double-blind trial in the elderly in recent years was 
recently reported.35 The trial was conducted in The 
Netherlands and involved 1838 people over the age of 60 
years but without major chronic illness (the Dutch Health 
Council does not list age as an indication for vaccina- 
tion). Vaccine was compared with a saline placebo, and 
the outcome was assessed as self-reported symptoms of 
influenza and serologic evidence of influenza infection. 
Vaccination significantly reduced both outcomes, and 
there was a 50% reduction in risk for both symptoms and 
positive serology 
PNELJMOCOCCAL VACCINE 
Studies in adults and children using the 14-valent and 23- 
valent polysaccharide vaccines indicate that they are well- 
tolerated.36-38 Approximately 50% of both adults and older 
children experience mild local reactions that are self-lim- 
iting. Systemic reactions in adults are rare; however, 
approximately 10% of children may experience fever. As 
these figures were determined in the absence of a 
placebo control, they are possibly overestimates. 
Although one study has reported severe reactions on 
revaccination,39 this has not been seen in other studies,*O 
although there may be some increase in local reaction 
due to an Arthus-type reaction.38 
Whereas the ability of pneumococcal vaccine to pro- 
tect young healthy adults has been clearly demonstrated 
in controlled trials,41-43 the effectiveness of pneumococ- 
cal vaccine in preventing pneumonia in the elderly and 
high-risk adults continues to be debated. Three random- 
ized controlled trials in the United States failed to show 
protective efficacy against pneumonia, and although there 
was a suggestion that the vaccine was protective against 
pneumococcal bacteremia this was not statistically sig- 
nificant.** However, it has been recognized that these tri- 
als lacked the necessary statistical power and that 
case-control studies offer the best possibility for testing 
the effectiveness of the vaccine and offer the advantage 
that it is not necessary to randomly withhold potentially 
life-saving immunization from high-risk individuals.*j Four 
of five case-control studies reported between 1984 and 
1995 indicate a vaccine effectiveness between 56% and 
81% in preventing invasive pneumococcal infection with 
serotypes present in the vaccine.46-50 One of these stud- 
ies demonstrated reduced effectiveness in an immuno- 
compromised subset of recipients.*’ 
An alternative approach has also been used for assess- 
ment of vaccine effectiveness. This method compares 
the distribution of pneumococcal serotypes isolated from 
normally sterile sites in vaccinated and unvaccinated indi- 
viduals.51 The study, which used data from the American 
Spneumoniae national disease surveillance, showed an 
overall effectiveness of 57 to 64%, similar to the results 
of the case-control studies. Efficacy could not be demon- 
strated in certain disease categories, including sickle cell 
disease, chronic renal failure, Hodgkin’s disease, and mul- 
tiple myeloma, where there were only small numbers of 
patients. Vaccination was effective, however, in people 
with heart disease, lung disease, and diabetes; and immu- 
nity may persist for as long as 9 years for most recipients. 
To date, studies in elderly and high-risk adults have failed 
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to demonstrate definite protection against pneurnococcal 
pneumonia; however, this may be due to limitations of 
the studies, and based on the earlier studies in healthy 
young adults, protection would certainly be expected. 
One potential weakness of the vaccine in this regard is 
that, because selection of the pneumococcal strains was 
based on the frequency of isolation from usually sterile 
sites, it may be possible that the vaccine is biased to pro- 
tection against bacteremia rather than pneumonia. The 
level of protection afforded against pneumococcal bac- 
teremia together with high mortality and morbidity argue 
strongly in favor of widespread vaccination in the elderly 
and high-risk adults for this reason alone.52 
ECONOMICS OF VACCINATION 
A number of recent studies and economic analyses have 
shown that influenza vaccination has a positive cost ben- 
efit in the American health care setting. Mullooly et al 
demonstrated that influenza vaccination of all elderly 
people contributed a net saving in a American health 
maintenance organization over a v-year study period.53 A 
recent S-year study by Nichol et al indicated an average 
cost benefit of US $117 per person per year in vacci- 
nated elderly people, and in a separate study they demon- 
strated a positive economic benefit from vaccinating 
healthy working adults. 33 An analysis of French data sim- 
ilarly demonstrated that vaccination of employed adults 
would be cost saving both globally and as an individual 
benefit to the vaccinated person.54 There are, however, 
few solid cost-benefit data currently available from other 
countries, and in particular economic data for vaccination 
of high-risk individuals. Scott and Scott have recently eval- 
uated the cost and benefits of influenza vaccination in 
individuals 65 years of age and older in New Zealand, by 
combining published overseas findings with New Zealand 
volume and unit cost data.55 They concluded that 
influenza vaccination was cost effective from the per- 
spective of society government, and the individual. How- 
ever, the need for country-specific data has recently been 
highlighted, and the European Scientific Working Group 
on Influenza has initiated a program to generate further 
socioeconomic data. 1,56,57 
The cost effectiveness of influenza vaccination has 
been compared with other health care interventions and 
was judged to be one of three procedures that yields an 
actual cost benefit.58 In this comparison pneumococcal 
vaccination was included on the basis of a 1986 analysis. 
The latter analysis was based on estimates of vaccine efti- 
ciency in preventing pneumococcal pneumonia, which 
have subsequently been questioned. Nevertheless cost- 
effectiveness estimates based on the effectiveness against 
pneumococcal bacteremia alone, although not cost sav- 
ing, still show pneumococcal vaccination to be among 
the most effective health care interventions in the 
elderly. 59 With an aging global population,6o effective 
immunization against influenza and pneumococcal infec- 
tion assume growing importance both in the context of 
healthy aging and effective allocation of health care 
resources. 
PROSPECTS FOR IMPROVED VACCINES 
Regardless of their achievements, the currently available 
influenza and pneumonia vaccines do have deficiencies. 
Recognition of the importance of influenza and pneu- 
monia as major causes of adult morbidity and mortality 
in developed countries and the prospect that they will 
assume a growing importance in developing countries 
indicates a need for more effective prevention. 
Improved Influenza Vaccines 
Current influenza vaccines induce primarily a serum 
immunoglobulin response. In theory, better protection 
and more rapid recovery from infection should result 
from a vaccine that also is capable of inducing both 
mucosal and cell-mediated immune responses. The effec- 
tiveness of current influenza vaccines is also highly 
dependent on achieving a close match between vaccine 
strains and circulating viruses; it would be better if vac- 
cines could produce a broader cross-reactive immunity. 
In addition, the long lead-time in producing egg-grown 
vaccines presents a problem in responding to yearly 
changes in the circulating viruses (antigenic drift) and 
can be disastrous in the face of a new pandemic strain 
(antigenic shift). Finally, although it has been suggested 
that the healthy elderly are still capable of mounting a sat- 
isfactory immune response to the vaccine, many of those 
with predisposing risk factors have diminished 
responses.31 All of these factors present challenges in the 
development of improved vaccines. 
For many years efforts were directed toward the 
development of living attenuated vaccines for influenza; 
however, the results obtained with these suggest that 
although they may be useful in children and possibly 
young adults, 61 they are unlikely to replace the current 
inactivated vaccines in older adults. More recently efforts 
have focused on the use of immunologic adjuvants, 
including liposomes, oil-in-water preparations, and prepa- 
rations based on quil A. Results reported at a recent 
international influenza meeting indicate that although a 
number of these adjuvants substantially improved the 
immunogenicity of influenza vaccines in experimental 
animals, to date those that have been administered to 
man have achieved only modest improvements in the 
humoral antibody response.62 Influenza viruses grown 
in cell culture and influenza hemagglutinins produced as 
an engineered baculovirus construct in insect cell culture 
have both been shown to be immunogenic in man and 
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may provide the opportunity to produce greater quan- 
tities of vaccine more rapidly than is currently possible 
with ernbryonated eggs. 63 Currently, there is considerable 
excitement regarding the prospect of immunization 
against influenza using DNA vaccines. Influenza has been 
used as one of the models for evaluating DNA vaccina- 
tion, and based on animal studies to date,64 these vac- 
cines offer a number of potential advantages, including 
improved antibody response to the viral surface anti- 
gens, generation of cell-mediated immunity, and the 
capacity for preparing large quantities of vaccine rapidly, 
ahead of epidemics and pandemics. However, caution 
must be exercised, as the performance of experimental 
influenza vaccines in laboratory animals is not neces- 
sarily a good indicator of their performance in man, and 
these new products still face many regulatory hurdles. 
Improved Pneumococcal Vaccines 
There are two major shortcomings with the current pneu- 
mococcal vaccines. First, the vaccine-induced protection 
is serotype specific, requiring multivalent vaccines with 
a large number of antigens and even the potential require- 
ment for vaccines with different formulations for differ- 
ent geographic regions. Second, polysaccharides are poor 
antigens, particularly in young children and certain of 
the risk groups, and they induce thymus-independent 
responses lacking immunologic memory. In addition, a 
number of the pneumococcal capsular polysaccharides 
are known to be poor immunogens. The development 
of improved pneumococcal vaccines is primarily focused 
on producing a vaccine that will induce an immune 
response in children under the age of 2 years. This is 
being approached by conjugation of the pneumococcal 
polysaccharides to protein carriers, a method that was 
successfully used in the development of Haemophihs 
influenzae type b vaccines. A limited study has already 
demonstrated that polysaccharide antigen conjugated to 
an outer membrane protein derived from Neisseria 
meningitidis will prime for improved polysaccharide 
responses in Hodgkin’s disease patientsG5 Recent studies 
have indicated that a number of pneumococcal protein 
antigens may play a role in generating protective immu- 
nity, particularly the pneumolysin toxin.@j An engineered 
toxoid version of this protein has been shown to induce 
partial immunity to challenge in mice, and the toxoid also 
appears to be an effective carrier protein for conjugation 
with pneumococcal polysaccharides.67 Although primar- 
ily intended for immunization of young children, a con- 
jugate vaccine involving pneumococcal carrier protein 
also has the potential to provide more effective immunity 
in the older adult and high-risk populations. 
Although improved vaccines may offer the potential 
for more effective control of influenza and pneumococ- 
cal infection, the unfortunate reality is that appropriate 
use is not made of currently available vaccines that have 
been shown to provide substantial protection to the at- 
risk population and economic benefits to society. 
Whereas the rate of influenza vaccination has increased 
significantly in many developed countries over recent 
years2 it is still believed to be far below 50% of the at- 
risk population in most countries. The usage rate of pneu- 
mococcal vaccine has been even more disappointing. In 
the United States, where pneumococcal vaccine is rec- 
ommended for all people 65 years of age and above, it 
has been estimated that only 28% of those who should 
receive vaccine have in fact received it.68 Vaccination in 
most other developed countries is almost nonexistent, 
and the reasons for this are not well understood. 
Clearly, if optimum gains from vaccination are to be 
achieved, not only is research directed to vaccine devel- 
opment required but also, and possibly more important, 
research to develop understanding of factors that deter- 
mine vaccination rates. Recent years have brought sub- 
stantial improvements in the understanding of the 
epidemiology of influenza and pneumococcal disease. 
Effective prevention of these diseases with current and 
new vaccines will likely depend on similar advances in 
the understanding of the epidemiology of how these vac- 
cines are used. 
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